Biotech · Public company · Boston, MA, US

Bicara Therapeutics Inc.

Ticker BCAX · SEC CIK 0002023658

Track this companyFree. Adds Bicara Therapeutics Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials55 recruiting or active

Pipeline programs4From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline4

Ficerafusp alfaPhase 3 · Metastatic Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Pembrolizumab (KEYTRUDA®)Phase 3 · Metastatic Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
BCA101Phase 1 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 1 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026

Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)PHASE1_PHASE2 · NOT_YET_RECRUITING · started Nov 30, 2026ClinicalTrials.gov NCT07552558 · fetched Nov 12, 2026
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCCPHASE2 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07807163 · fetched Nov 12, 2026
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCCPHASE2 · RECRUITING · started Mar 26, 2026ClinicalTrials.gov NCT07465276 · fetched Nov 12, 2026
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCPHASE2_PHASE3 · RECRUITING · started Jan 28, 2025ClinicalTrials.gov NCT06788990 · fetched Nov 12, 2026
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid TumorsPHASE1 · RECRUITING · started Jun 1, 2020ClinicalTrials.gov NCT04429542 · fetched Nov 12, 2026